Friday, 13 July 2012

Femtrace


Generic Name: estradiol oral (ess tra DYE ole)

Brand Names: Estrace, Femtrace, Gynodiol


What is estradiol oral?

Estradiol is a form of estrogen, a female sex hormone produced by the ovaries. Estrogen is necessary for many processes in the body.


Estradiol is used to treat symptoms of menopause such as hot flashes, and vaginal dryness, burning, and irritation. Other uses include prevention of osteoporosis in postmenopausal women, and replacement of estrogen in women with ovarian failure or other conditions that cause a lack of natural estrogen in the body. Estradiol is sometimes used as part of cancer treatment in women and men.


Estradiol may also be used for other purposes not listed in this medication guide.


What is the most important information I should know about estradiol oral?


Estradiol can harm an unborn baby or cause birth defects. Do not use estradiol if you are pregnant. You should not take estradiol if you have abnormal vaginal bleeding, liver disease, breast or uterine cancer, hormone-dependent cancer, a recent history of heart attack or stroke, if you are pregnant, if you have ever had a blood clot (especially in your lung or your lower body), or if you are allergic to any medicines or food dyes. Taking hormones can increase your risk of blood clots, stroke, or heart attack, especially if you have diabetes, high blood pressure, high cholesterol or triglycerides, if you smoke, or if you are overweight.

Long-term estradiol treatment may increase your risk of breast cancer, ovarian cancer, or uterine cancer. Talk with your doctor about your individual risks before using estradiol long-term. Your doctor should check your progress every 3 to 6 months to determine whether you should continue this treatment.


Taking progestin while using estradiol may lower your risk of uterine cancer. If your uterus has not been removed, your doctor may prescribe a progestin for you to take while you are using estradiol.


Estradiol should not be used to prevent heart disease, stroke, or dementia, because this medication may actually increase your risk of developing these conditions.


Have regular physical exams and mammograms, and self-examine your breasts for lumps on a monthly basis while using estradiol.


What should I discuss with my health care provider before using estradiol oral?


You should not take estradiol if you are allergic to it, or if you have:
  • liver disease;


  • abnormal vaginal bleeding that a doctor has not checked;




  • any type of breast, uterine, or hormone-dependent cancer;




  • a recent history of heart attack or stroke;




  • if you are pregnant;




  • if you have ever had a blood clot (especially in your lung or your lower body); or




  • if you are allergic to any medicines or food dyes.




Taking hormones can increase your risk of blood clots, stroke, or heart attack, especially if you have risk factors such as diabetes, high blood pressure, high cholesterol or triglycerides, smoking, or being overweight.

To make sure you can safely take estradiol, tell your doctor if you have any of these other conditions:



  • heart disease;



  • kidney disease;


  • family history of blood clots;




  • a history of jaundice caused by pregnancy or taking hormones;




  • endometriosis;




  • lupus;




  • porphyria;




  • gallbladder disease;




  • underactive thyroid;




  • asthma;




  • epilepsy or other seizure disorder;




  • migraines;




  • low levels of calcium in your blood; or




  • if you have had your uterus removed (hysterectomy).




FDA pregnancy category X. This medication can harm an unborn baby or cause birth defects. Do not use estradiol if you are pregnant. Tell your doctor right away if you become pregnant during treatment. Estradiol can pass into breast milk and may harm a nursing baby. This medication may also slow breast milk production. You should not breast-feed while you are taking estradiol. Estradiol should not be used to prevent heart disease, stroke, or dementia, because this medication may actually increase your risk of developing these conditions.

How should I use estradiol oral?


Take this medication exactly as it was prescribed for you. Do not use the medication in larger amounts, or use it for longer than recommended by your doctor.


Long-term estradiol treatment may increase your risk of breast cancer, ovarian cancer, or uterine cancer. Talk with your doctor about your individual risks before using estradiol long-term.


Taking progestin while using estradiol may lower your risk of uterine cancer. If your uterus has not been removed, your doctor may prescribe a progestin for you to take while you are using estradiol.


Have regular physical exams and mammograms, and self-examine your breasts for lumps on a monthly basis while using estradiol. Your doctor should check your progress every 3 to 6 months to determine whether you should continue this treatment.


If you need medical tests or surgery, or if you will be on bed rest, you may need to stop using this medication for a short time. Any doctor or surgeon who treats you should know that you are taking estradiol. Store at room temperature away from moisture, heat, and light.

What happens if I miss a dose?


Take the missed dose as soon as you remember. Skip the missed dose if it is almost time for your next scheduled dose. Do not take extra medicine to make up the missed dose.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

Overdose can cause nausea, vomiting, or vaginal bleeding.


What should I avoid while using estradiol oral?


Do not smoke while using this medication. Smoking can increase your risk of blood clots, stroke, or heart attack caused by estradiol.

Estradiol oral side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop using estradiol and call your doctor at once if you have a serious side effect such as:

  • unusual vaginal bleeding (especially if you are past menopause);




  • chest pain or heavy feeling, pain spreading to the arm or shoulder, nausea, sweating, general ill feeling;




  • sudden numbness or weakness, especially on one side of the body;




  • sudden severe headache, confusion, problems with vision, speech, or balance;




  • stabbing chest pain, sudden cough, wheezing, rapid breathing, fast heart rate;




  • pain, swelling, warmth, or redness in one or both legs;




  • nausea, vomiting, loss of appetite, increased thirst, muscle weakness, confusion, and feeling tired or restless;




  • a lump in your breast;




  • feeling like you might pass out;




  • pain, swelling, or tenderness in your stomach; or




  • jaundice (yellowing of the skin or eyes).



Less serious side effects may include:



  • mild nausea, vomiting, bloating, stomach cramps;




  • breast pain, tenderness, or swelling;




  • freckles or darkening of facial skin;




  • loss of scalp hair;




  • vaginal itching or discharge; or




  • changes in your menstrual periods, break-through bleeding.



This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect estradiol oral?


Tell your doctor about all other medicines you use, especially:



  • a blood thinner such as warfarin (Coumadin);




  • cimetidine (Tagamet);




  • carbamazepine (Carbatrol, Tegretol);




  • phenobarbital (Luminal, Solfoton);




  • phenytoin (Dilantin);




  • rifampin (Rifadin, Rifater, Rifamate, Rimactane); or




  • ritonavir (Norvir);




  • St. John's wort;




  • an antibiotic such as clarithromycin (Biaxin) or erythromycin (E-Mycin, E.E.S., Erythrocin, Ery-Tab); or




  • antifungal medication such as ketoconazole (Extina, Ketozole, Nizoral, Xolegal).



This list is not complete and other drugs may interact with estradiol. Tell your doctor about all medications you use. This includes prescription, over-the-counter, vitamin, and herbal products. Do not start a new medication without telling your doctor.



More Femtrace resources


  • Femtrace Side Effects (in more detail)
  • Femtrace Dosage
  • Femtrace Use in Pregnancy & Breastfeeding
  • Drug Images
  • Femtrace Drug Interactions
  • Femtrace Support Group
  • 0 Reviews for Femtrace - Add your own review/rating


  • Femtrace MedFacts Consumer Leaflet (Wolters Kluwer)

  • Femtrace Advanced Consumer (Micromedex) - Includes Dosage Information

  • Femtrace Consumer Overview

  • Femtrace Prescribing Information (FDA)

  • estradiol Transdermal Advanced Consumer (Micromedex) - Includes Dosage Information

  • Estradiol Prescribing Information (FDA)

  • Estradiol Monograph (AHFS DI)

  • Estradiol Professional Patient Advice (Wolters Kluwer)

  • Estradiol MedFacts Consumer Leaflet (Wolters Kluwer)

  • Alora Prescribing Information (FDA)

  • Alora Advanced Consumer (Micromedex) - Includes Dosage Information

  • Climara Weekly Patch MedFacts Consumer Leaflet (Wolters Kluwer)

  • Climara Consumer Overview

  • Climara Prescribing Information (FDA)

  • Delestrogen Prescribing Information (FDA)

  • Delestrogen MedFacts Consumer Leaflet (Wolters Kluwer)

  • Depo-Estradiol MedFacts Consumer Leaflet (Wolters Kluwer)

  • Depo-Estradiol Prescribing Information (FDA)

  • Estrace Prescribing Information (FDA)

  • Estrace Advanced Consumer (Micromedex) - Includes Dosage Information

  • Estrace MedFacts Consumer Leaflet (Wolters Kluwer)

  • Estrace Consumer Overview

  • Estraderm Patch MedFacts Consumer Leaflet (Wolters Kluwer)

  • Estraderm Prescribing Information (FDA)

  • Estradiol Patch Prescribing Information (FDA)

  • Estrasorb Emulsion MedFacts Consumer Leaflet (Wolters Kluwer)

  • Estrasorb Consumer Overview

  • Estrasorb Prescribing Information (FDA)

  • Evamist Spray MedFacts Consumer Leaflet (Wolters Kluwer)

  • Evamist Prescribing Information (FDA)

  • Evamist Consumer Overview

  • Femring Ring MedFacts Consumer Leaflet (Wolters Kluwer)

  • Femring Prescribing Information (FDA)

  • Menostar Consumer Overview

  • Menostar Prescribing Information (FDA)

  • Menostar Weekly Patch MedFacts Consumer Leaflet (Wolters Kluwer)

  • Vivelle Prescribing Information (FDA)

  • Vivelle-Dot Prescribing Information (FDA)



Compare Femtrace with other medications


  • Postmenopausal Symptoms


Where can I get more information?


  • Your pharmacist can provide more information about estradiol.

See also: Femtrace side effects (in more detail)


Wednesday, 11 July 2012

Axid AR


Pronunciation: ni-ZA-ti-dine
Generic Name: Nizatidine
Brand Name: Axid and Axid AR


Axid AR is used for:

Treating and preventing ulcers. It is also used to treat gastroesophageal reflux disease (GERD) and to treat and maintain healing of erosive esophagitis. It may also be used for other conditions as determined by your health care provider.


Axid AR is a histamine H2antagonist. It works by reducing acid in the stomach by blocking one of the chemicals (histamine) that stimulates the production of stomach acid.


Do NOT use Axid AR if:


  • you are allergic to any ingredient in Axid AR or other H2 antagonists (eg, famotidine)

Contact your doctor or health care provider right away if any of these apply to you.



Before using Axid AR:


Some medical conditions may interact with Axid AR. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have kidney or liver problems

  • if you have a history of the blood disease porphyria

Some MEDICINES MAY INTERACT with Axid AR. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Ketoconazole because effectiveness may be decreased by Axid AR

This may not be a complete list of all interactions that may occur. Ask your health care provider if Axid AR may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Axid AR:


Use Axid AR as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Axid AR maybe taken with or without food.

  • Continue to use Axid AR even if you feel well. Do not miss any doses.

  • Antacids may be taken as needed to help relieve stomach pain, unless your health care provider instructed otherwise.

  • If you miss a dose of Axid AR, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Axid AR.



Important safety information:


  • Axid AR may cause dizziness. Do not drive, operate machinery, or do anything else that could be dangerous until you know how you react to Axid AR. Using Axid AR alone, with other medicines, or with alcohol may lessen your ability to drive or to perform other potentially dangerous tasks.

  • Use Axid AR with extreme caution in the ELDERLY because they may be more sensitive to its effects.

  • Use Axid AR with extreme caution in CHILDREN younger than 12 years of age. Safety and effectiveness in this age group have not been confirmed.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant while taking Axid AR, discuss with your doctor the benefits and risks of using Axid AR during pregnancy. Axid AR is excreted in breast milk. Do not breast-feed while taking Axid AR.


Possible side effects of Axid AR:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Diarrhea; dizziness; headache.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue).



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Axid AR side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include difficulty breathing; fast heartbeat; restlessness; tremor; vomiting.


Proper storage of Axid AR:

Store Axid AR at room temperature, between 59 and 86 degrees F (15 and 30 degrees C), in a tightly closed container. Store away from heat, moisture, and light. Do not store in the bathroom. Keep Axid AR out of the reach of children and away from pets.


General information:


  • If you have any questions about Axid AR, please talk with your doctor, pharmacist, or other health care provider.

  • Axid AR is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Axid AR. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Axid AR resources


  • Axid AR Side Effects (in more detail)
  • Axid AR Use in Pregnancy & Breastfeeding
  • Axid AR Drug Interactions
  • Axid AR Support Group
  • 1 Review for Axid AR - Add your own review/rating


  • Axid AR Prescribing Information (FDA)

  • Nizatidine Prescribing Information (FDA)

  • Nizatidine Professional Patient Advice (Wolters Kluwer)

  • Axid Monograph (AHFS DI)

  • Axid Consumer Overview

  • Axid Prescribing Information (FDA)



Compare Axid AR with other medications


  • Duodenal Ulcer
  • Duodenal Ulcer Prophylaxis
  • Erosive Esophagitis
  • GERD
  • Indigestion
  • Stomach Ulcer

Tuesday, 10 July 2012

Non-iodinated contrast media


A drug may be classified by the chemical type of the active ingredient or by the way it is used to treat a particular condition. Each drug can be classified into one or more drug classes.

See also

Medical conditions associated with non-iodinated contrast media:

  • Computed Tomography

Drug List:

Monday, 9 July 2012

Gas Free Extra Strength


Generic Name: simethicone (sye METH i cone)

Brand Names: Alka-Seltzer Anti-Gas, Equalize Gas Relief Drops, Gas Aide, Gas Free Extra Strength, Gas-X, Gas-X Extra Strength, Gas-X Infant Drops, Gas-X Maximum Strength, Gas-X Thin Strips Cinnamon, Gas-X Thin Strips Peppermint, Gas-X Tongue Twisters Thin Strips Children's, Gas-X Ultra Softgels, Genasyme, Infantaire Gas Relief, Little Tummys, Maalox Anti-Gas, Maalox Anti-Gas Extra Strength, Mi-Acid Gas Relief, Mylanta Gas, Mylanta Gas Maximum Strength, Mylicon, Mytab Gas, Phazyme, Phazyme Maximum Strength, Phazyme Ultra, Phazyme-125, Phazyme-95


What is Gas Free Extra Strength (simethicone)?

Simethicone allows gas bubbles in the stomach and intestines to come together more easily, which allows for easier passage of gas.


Simethicone is used to relieve painful pressure caused by excess gas in the stomach and intestines. Simethicone is for use in babies, children, and adults.


Simethicone may also be used for purposes not listed in this medication guide.


What is the most important information I should know about Gas Free Extra Strength (simethicone)?


Never use more than the recommended dose of simethicone.

Ask a doctor or pharmacist if it is safe for you to take this medicine if you are allergic to any drugs, or if you have any type of serious illness (especially one that affects your stomach or intestines).


Simethicone works best if you take it after meals and at bedtime.


Simethicone may be only part of a complete program of treatment that may also include a special diet or increased exercise. It is very important to follow the diet and exercise plan created for you by your doctor or nutrition counselor. You should become very familiar with the list of foods you must avoid to help control your condition.


There may be other drugs that can interact with simethicone. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.


What should I discuss with my healthcare provider before taking Gas Free Extra Strength (simethicone)?


You should not use this medication if you are allergic to simethicone.

Ask a doctor or pharmacist if it is safe for you to take this medicine if you are allergic to any drugs, or if you have any type of serious illness (especially one that affects your stomach or intestines).


Simethicone is not expected to harm an unborn baby. It is not known whether simethicone passes into breast milk or if it could harm a nursing baby. Do not use this medication without medical advice if you are breast-feeding a baby.

The liquid form may contain phenylalanine. Talk to your doctor before using this form of simethicone if you have phenylketonuria (PKU).


How should I take Gas Free Extra Strength (simethicone)?


Use exactly as directed on the label, or as prescribed by your doctor. Do not use in larger or smaller amounts or for longer than recommended.


Do not take more of this medication than is directed.

Simethicone works best if you take it after meals and at bedtime.


The simethicone chewable tablet must be chewed before swallowing.


Measure liquid medicine with a special dose measuring spoon or medicine cup, not with a regular table spoon. If you do not have a dose measuring device, ask your pharmacist for one. Clean the medicine dropper after each use. Allow it to air dry.


Simethicone liquid drops can be mixed with water, baby formula, or other liquids to make swallowing easier for an infant or child.


Children should never be given more than the recommended dose of simethicone. Call your doctor if the child's gas symptoms do not improve after treatment with simethicone.

Simethicone may be only part of a complete program of treatment that may also include a special diet or increased exercise. It is very important to follow the diet and exercise plan created for you by your doctor or nutrition counselor. You should become very familiar with the list of foods you must avoid to help control your condition.


Store at room temperature away from moisture, heat, and light. Do not allow the liquid form of this medicine to freeze.

What happens if I miss a dose?


Since simethicone is used on an as needed basis, you are not likely to miss a dose. Do not use more of this medication than is directed.


What happens if I overdose?


Seek emergency medical attention or call the Poison Help line at 1-800-222-1222.

What should I avoid while taking Gas Free Extra Strength (simethicone)?


Ask a doctor or pharmacist before using any other stomach medicine or antacid. Simethicone is contained in many combination medicines. Taking certain products together can cause you to get too much simethicone.


Gas Free Extra Strength (simethicone) side effects


Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


What other drugs will affect Gas Free Extra Strength (simethicone)?


There may be other drugs that can interact with simethicone. Tell your doctor about all your prescription and over-the-counter medications, vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start a new medication without telling your doctor.



More Gas Free Extra Strength resources


  • Gas Free Extra Strength Side Effects (in more detail)
  • Gas Free Extra Strength Use in Pregnancy & Breastfeeding
  • Drug Images
  • Gas Free Extra Strength Support Group
  • 0 Reviews for Gas Free Extra Strength - Add your own review/rating


  • Simethicone Professional Patient Advice (Wolters Kluwer)

  • Simethicone Monograph (AHFS DI)

  • Alka-Seltzer Anti-Gas Advanced Consumer (Micromedex) - Includes Dosage Information

  • Bicarsim MedFacts Consumer Leaflet (Wolters Kluwer)

  • Gas-X Chewable Tablets MedFacts Consumer Leaflet (Wolters Kluwer)

  • Gas-X Extra Strength MedFacts Consumer Leaflet (Wolters Kluwer)

  • Gas-X Infant Drops Liquid Drops MedFacts Consumer Leaflet (Wolters Kluwer)

  • Genasyme Suspension MedFacts Consumer Leaflet (Wolters Kluwer)



Compare Gas Free Extra Strength with other medications


  • Endoscopy or Radiology Premedication
  • Functional Gastric Disorder
  • Gas
  • Postoperative Gas Pains


Where can I get more information?


  • Your pharmacist can provide more information about simethicone.

See also: Gas Free Extra Strength side effects (in more detail)


Friday, 6 July 2012

Abraxane 5 mg / ml powder for suspension for infusion





1. Name Of The Medicinal Product



Abraxane 5 mg/ml powder for suspension for infusion.


2. Qualitative And Quantitative Composition



Each vial contains 100 mg of paclitaxel (as paclitaxel albumin).



After reconstitution, each ml of suspension contains 5 mg of paclitaxel (as paclitaxel albumin).



Excipients



The reconstituted medicinal product contains approximately 425 mg sodium per dose.



For a full list of excipients, see section 6.1.



3. Pharmaceutical Form



Powder for suspension for infusion.



The reconstituted suspension has a pH of 6-7.5 and an osmolality of 300-360 mOsm/kg.



The powder is white to yellow.



4. Clinical Particulars



4.1 Therapeutic Indications



Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated (see section 4.4).



4.2 Posology And Method Of Administration



Posology



The recommended dose of Abraxane is 260 mg/m2 administered intravenously over 30 minutes every 3 weeks.



Dose adjustments during treatment:



Patients who experience severe neutropenia (neutrophil count < 0.50 x 109/l for a week or longer) or severe sensory neuropathy during Abraxane therapy should have the dose reduced to 220 mg/m2 for subsequent courses. Following recurrence of severe neutropenia or severe sensory neuropathy, additional dose reduction should be made to 180 mg/m2. Abraxane should not be administered until neutrophil counts recover to >1.5 x 109/l. For grade 3 sensory neuropathy withhold treatment until resolution to grade 1 or 2, followed by a dose reduction for all subsequent courses.



Patients with hepatic impairment:



Insufficient data are currently available to recommend dose modifications in patients with mild to moderate hepatic impairment that ensure acceptable toxicity while maintaining efficacy. Patients with severe hepatic impairment should not be treated with paclitaxel (see sections 4.4.and 5.2).



Patients with impaired renal function:



Studies in patients with impaired renal function have not been performed and insufficient data are currently available to recommend dose modifications in patients with renal impairment (see section 5.2).



Paediatric population:



The safety and efficacy of Abraxane in children has not been established. There is no relevant use of Abraxane in the paediatric population in the indication of metastatic breast cancer.



Elderly patients:



In the clinical studies, no toxicities occurred notably more frequently among elderly patients who received Abraxane.



Method of administration



Abraxane should only be administered under the supervision of a qualified oncologist in units specialised in the administration of cytotoxic agents.



For instructions on reconstitution of the medicinal product before administration, see section 6.6.



4.3 Contraindications



Hypersensitivity to the active substance or to any of the excipients.



Lactation.



Patients who have baseline neutrophil counts < 1.5 x 109/l.



4.4 Special Warnings And Precautions For Use



Abraxane is an albumin-bound nanoparticle formulation of paclitaxel, which may have substantially different pharmacological properties compared to other formulations of paclitaxel (see sections 5.1 and 5.2). It should not be substituted for or with other paclitaxel formulations.



Hypersensitivity:



If hypersensitivity occurs, the medicinal product should be discontinued immediately, symptomatic treatment should be initiated, and that patient should not be rechallenged with paclitaxel.



Haematology:



Bone marrow suppression (primarily neutropenia) occurs frequently with Abraxane. Neutropenia is dose-dependent and a dose-limiting toxicity. Frequent monitoring of blood cell counts should be performed during Abraxane therapy. Patients should not be retreated with subsequent cycles of Abraxane until neutrophils recover to >1.5 x 109/l and platelets recover to >100 x 109/l.



Neuropathy:



Sensory neuropathy occurs frequently with Abraxane, although development of severe symptoms is less common. The occurrence of grade 1 or 2 sensory neuropathy does not generally require dose reduction. If grade 3 sensory neuropathy develops, treatment should be withheld until resolution to grade 1 or 2 followed by a dose reduction for all subsequent courses of Abraxane is recommended (see section 4.2).



Hepatic impairment:



Because the toxicity of paclitaxel can be increased with hepatic impairment, administration of Abraxane in patients with hepatic impairment should be performed with caution. Patients with hepatic impairment may be at increased risk of toxicity, particularly from myelosuppression, and such patients should be closely monitored for development of profound myelosuppression.



Patients with severe hepatic impairment (bilirubin > 5 x ULN or AST/ALT > 10 x ULN) have not been studied and should not be treated with Abraxane. The appropriate dose regimen in patients with less severe hepatic impairment is unknown. A dose reduction in patients with bilirubin >2 ULN must be considered since paclitaxel clearance is decreased in patients with high bilirubin levels (see section 5.2).



Cardiotoxicity:



Rare reports of congestive heart failure and left ventricular dysfunction have been observed among individuals receiving Abraxane. Most of the individuals were previously exposed to cardiotoxic drugs, such as anthracyclines, or had underlying cardiac history.Thus patients receiving Abraxane should be vigilantly monitored by physicians for the occurrence of cardiac events.



CNS metastases:



The effectiveness and safety of Abraxane in patients with central nervous system (CNS) metastases has not been established. CNS metastases are generally not well controlled by systemic chemotherapy.



Gastrointestinal symptoms:



If patients experience nausea, vomiting and diarrhoea following the administration of Abraxane, they may be treated with commonly used anti-emetics and constipating agents.



Excipients:



When reconstituted, Abraxane contains approximately 425 mg sodium per dose. To be taken into consideration by patients on a controlled sodium diet.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



No interaction studies have been performed.



The metabolism of paclitaxel is catalysed, in part, by cytochrome P450 isoenzymes CYP2C8 and CYP3A4 (see section 5.2). Therefore, caution should be exercised when administering paclitaxel concomitantly with medicines known to inhibit (e.g. ketoconazole and other imidazole antifungals,erythromycin, fluoxetine, gemfibrozil, cimetidine, ritonavir, saquinavir, indinavir, and nelfinavir)) or induce (e.g. rifampicin, carbamazepine, phenytoin, efavirenz, nevirapine) either CYP2C8 or CYP3A4.



Abraxane is indicated for mono-therapy. Abraxane should not be used in combination with other anticancer agents.



4.6 Pregnancy And Lactation



Contraception in males and females



Women of childbearing potential should use effective contraception during and up to 1 month after receiving treatment with Abraxane. Male patients treated with Abraxane are advised not to father a child during and up to six months after treatment.



Pregnancy:



There are very limited data on the use of paclitaxel in human pregnancy. Paclitaxel is suspected to cause serious birth defects when administered during pregnancy. Studies in animals have shown reproductive toxicity (see section 5.3). Abraxane should not be used in pregnancy, and in women of childbearing potential not using effective contraception, unless the clinical condition of the mother requires treatment with paclitaxel.



Breastfeeding:



It is not known if paclitaxel is excreted in human milk. Because of potential serious adverse reactions in breast-feeding infants, Abraxane is contraindicated during lactation. Breastfeeding must be discontinued for the duration of therapy.



Fertility:



Abraxane induced infertility in male rats (see section 5.3). Male patients should seek advice on conservation of sperm prior to treatment because of the possibility of irreversible infertility due to therapy with Abraxane.



Sexually active men and women should use effective methods of contraception during treatment and up to six months after treatment for men, and one month after treatment for women.



4.7 Effects On Ability To Drive And Use Machines



Abraxane has minor or moderate influence on the ability to drive and use machines. Abraxane may cause adverse reactions such as tiredness (very common) and dizziness (common) that may affect the ability to drive and use machinery. Patients should be advised not to drive and use machines if they feel tired or dizzy.



4.8 Undesirable Effects



The following are the most common and important incidences of adverse reactions related to 229 patients with metastatic breast cancer who were treated with 260 mg/m2 Abraxane once every three weeks in the pivotal phase III clinical study.



Blood and lymphatic system disorders: Neutropenia was the most notable important haematological toxicity (reported in 79% of patients), and was rapidly reversible and dose dependent; leukopenia was reported in 71% of patients. Grade 4 neutropenia (< 0.5 x 109/l) occurred in 9% of patients treated with Abraxane. Febrile neutropenia occurred in four patients on Abraxane. Anaemia (Hb < 10 g/dl) was observed in 46% of patients on Abraxane, and was severe (Hb < 8 g/dl) in three cases. Lymphopenia was observed in 45% of the patients.



Nervous system disorders: In general, the frequency and severity of neurotoxicity was dose-dependent in patients receiving Abraxane. Peripheral neuropathy (mostly Grade 1 or 2 sensory neuropathy) was observed in 68% of patients on Abraxane with 10% being Grade 3, and no cases of Grade 4.



Gastrointestinal disorders: Nausea occurred in 29% of the patients and diarrhoea in 25% of the patients.



Skin and subcutaneous tissue disorders: Alopecia was observed in 90% of the patients treated with Abraxane.



Musculoskeletal and connective tissue disorders: Arthralgia occurred in 32% of patients on Abraxane and was severe in 6% of cases. Myalgia occurred in 24% of patients on Abraxane and was severe in 7% of cases. The symptoms were usually transient, typically occurred three days after Abraxane administration and resolved within a week.



General disorders and administration site conditions: Asthenia/Fatigue was reported in 40% of the patients.



Table 1 lists adverse reactions associated with the administration of Abraxane to patients from studies in which Abraxane has been administered as a single agent at any dose in any indication (N = 789).



The frequency of undesirable effects listed in table 1 is defined using the following convention:



Very common (



Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
















































Table 1: Adverse reactions reported with Abraxane at any dose in clinical studies.


 


Infections and infestations




Common: Infection, urinary tract infection, folliculitis, upper respiratory tract infection, candidiasis, sinusitis



Uncommon: Oral candidiasis, nasopharyngitis, cellulitis, herpes simplex, viral infection, pneumonia, catheter-related infection, fungal infection, herpes zoster, injection site infection




Neoplasms benign, malignant and unspecified (including cysts and polyps)




Uncommon: Metastatic pain, tumour necrosis




Blood and lymphatic system disorders




Very Common: Neutropenia, anaemia, leukopenia, thrombocytopenia, lymphopenia, bone marrow suppression



Common: Febrile neutropenia



Rare: Pancytopenia




Immune system disorders




Uncommon1: Hypersensitivity



Rare: Severe hypersensitivity




Metabolism and nutrition disorders




Very common: Anorexia



Common: Dehydration, decreased appetite, hypokalaemia



Uncommon: Hypophosphataemia, fluid retention, hypoalbuminaemia, polydipsia, hyperglycaemia, hypocalcaemia, hypoglycaemia, hyponatraemia




Psychiatric disorders




Common: Insomnia, depression, anxiety



Uncommon: Restlessness




Nervous system disorders




Very Common: Peripheral neuropathy, neuropathy, hypoaesthesia, paraesthesia.



Common: Peripheral sensory neuropathy, headache, dysgeusia, dizziness, peripheral motor neuropathy, ataxia, sensory disturbance, somnolence.



Uncommon: Polyneuropathy, areflexia, dyskinesia, hyporeflexia, neuralgia, sensory loss, syncope, postural dizziness, neuropathic pain, tremor




Eye disorders




Common: Increased lacrimation, blurred vision, dry eye, keratoconjunctivitis sicca, madarosis



Uncommon: Eye irritation, eye pain, abnormal vision, reduced visual acuity, conjunctivitis, visual disturbance, eye pruritus, keratitis




Ear and labyrinth disorders




Common: Vertigo



Uncommon: Ear pain, tinnitus




Cardiac disorders




Common: Tachycardia, arrhythmia, supraventricular tachycardia



Rare: bradycardia, cardiac arrest, left ventricular dysfunction, congestive heart failure




Vascular disorders




Common: Flushing, hot flushes, hypertension, lymphoedema



Uncommon: Hypotension, peripheral coldness, orthostatic hypotension



Rare: Thrombosis




Respiratory, thoracic and mediastinal disorders




Common: Dyspnoea, epistaxis, pharyngolaryngeal pain, cough, rhinitis, rhinorrhoea



Uncommon: Productive cough, exertional dyspnoea, sinus congestion, decreased breath sounds, pleural effusion, allergic rhinitis, hoarseness, nasal congestion, nasal dryness, wheezing, pulmonary emboli, pulmonary thromboembolism



Rare: Interstitial pneumonitis




Gastrointestinal disorders




Very Common: Nausea, diarrhoea, vomiting, constipation, stomatitis



Common: Abdominal pain, abdominal distension, upper abdominal pain, dyspepsia, gastrooesophageal reflux disease, oral hypoaesthesia



Uncommon: Dysphagia, flatulence, glossodynia, dry mouth, gingival pain, loose stools, oesophagitis, lower abdominal pain, mouth ulceration, oral pain, rectal haemorrhage




Hepatobiliary disorders




Uncommon: Hepatomegaly




Skin and subcutaneous tissue disorders




Very Common: Alopecia, rash



Common: Nail disorder, pruritus, dry skin, erythema, nail pigmentation/discolouration, skin hyperpigmentation, onycholysis, nail changes



Uncommon: Nail bed tenderness, urticaria, skin pain, photosensitivity reaction, pigmentation disorder, pruritic rash, skin disorder, hyperhidrosis, onychomadesis, erythematous rash, generalised rash, dermatitis, night sweats, maculo-papular rash, vitiligo, hypotrichosis, nail discomfort, generalized pruritus, macular rash, papular rash, skin lesion, swollen face



Very rare: Stevens-Johnson syndrome2, toxic epidermal necrolysis2




Musculoskeletal and connective tissue disorders




Very Common: Arthralgia, myalgia.



Common: Pain in extremity, bone pain, back pain, muscle cramps, limb pain



Uncommon: Chest wall pain, muscular weakness, neck pain, groin pain, muscle spasms, musculoskeletal pain, flank pain, limb discomfort, muscle weakness




Renal and urinary disorders




Uncommon: Dysuria, pollakiuria, haematuria, nocturia, polyuria, urinary incontinence




Reproductive system and breast disorders




Uncommon: Breast pain




General disorders and administration site conditions




Very Common: Fatigue, asthenia, pyrexia.



Common: Peripheral oedema, mucosal inflammation, pain, rigors, oedema, weakness, decreased performance status, chest pain, influenza-like illness, malaise, lethargy, hyperpyrexia



Uncommon: Chest discomfort, abnormal gait, swelling, injection site reaction



Rare: Extravasation




Investigations




Common: Decreased weight, increased alanine aminotransferase, increased aspartate aminotransferase, decreased haematocrit, decreased red blood cell count, increased body temperature, increased gamma-glutamyltransferase, increased blood alkaline phosphatase



Uncommon: Increased blood pressure, increased weight, increased blood lactate dehydrogenase, increased blood creatinine, increased blood glucose, increased blood phosphorus, decreased blood potassium, increased bilirubin




Injury, poisoning and procedural complications




Uncommon: Contusion



Rare: Radiation recall phenomenon, radiation pneumonitis



1 The frequency of hypersensitivity reactions is calculated based on one definitely related case in a population of 789 patients



2 As reported in the postmarketing surveillance of Abraxane.



Post-marketing experience:



Cranial nerve palsies, vocal cord paresis, and rare reports of severe hypersensitivity reactions have been reported during post-marketing surveillance of Abraxane.



In some patients previously exposed to capecitabine, reports of palmar-plantar erythrodysaesthesiae have been reported as part of the continuing surveillance of Abraxane. Because these events have been reported voluntarily during clinical practice, true estimates of frequency cannot be made and a causal relationship to the events has not been established.



4.9 Overdose



There is no known antidote for paclitaxel overdose. In the event of an overdose, the patient should be closely monitored. Treatment should be directed at the major anticipated toxicities, which are bone marrow suppression, mucositis and peripheral neuropathy.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Pharmacotherapeutic group: Taxanes, ATC Code: L01CD01



Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability results in the inhibition of the normal dynamic reorganisation of the microtubule network that is essential for vital interphase and mitotic cellular functions. In addition, paclitaxel induces abnormal arrays or “bundles” of microtubules throughout the cell cycle and multiple asters of microtubules during mitosis.



Abraxane contains human serum albumin-paclitaxel nanoparticles, where the paclitaxel is present in a non-crystalline, amorphous state. Albumin is known to mediate endothelial transcytosis of plasma constituents and in vitro studies demonstrated that the presence of albumin enhances transport of paclitaxel across endothelial cells. It is hypothesised that this enhanced transendothelial transport is mediated by the gp-60 albumin receptor, and that there is accumulation of paclitaxel in the area of tumour due to the albumin-binding protein SPARC (secreted protein acidic rich in cysteine).



Breast carcinoma:



Data from 106 patients accrued in two single-arm open-label studies and from 454 patients treated in a randomised Phase III comparative study are available to support the use of Abraxane in metastatic breast cancer. This information is presented below.



Single-arm open-label studies:



In one study, Abraxane was administered as a 30-minute infusion at a dose of 175 mg/m2 to 43 patients with metastatic breast cancer. The second trial utilised a dose of 300 mg/m2 as a 30 minute infusion in 63 patients with metastatic breast cancer. Patients were treated without steroid pre-treatment or planned G-CSF support. Cycles were administered at 3 week intervals. The response rates in all patients were 39.5% (95% CI: 24.9%-54.2%) and 47.6% (95% CI: 35.3%-60.0%), respectively. The median time to disease progression was 5.3 months (175 mg/m2; 95% CI: 4.6-6.2 months) and 6.1 months (300 mg/m2; 95% CI: 4.2-9.8 months).



Randomised comparative study:



This multi-centre trial was conducted in patients with metastatic breast cancer, who were treated every 3 weeks with single-agent paclitaxel, either as solvent-based paclitaxel 175 mg/m2 given as a 3-hour infusion with premedication to prevent hypersensitivity (N = 225), or as Abraxane 260 mg/m2 given as a 30 minute infusion without premedication (N = 229).



Sixty-four percent of patients had impaired performance status (ECOG 1 or 2) at study entry; 79% had visceral metastases; and 76% had > 3 sites of metastases. Fourteen percent of the patients had not received prior chemotherapy; 27% had received chemotherapy in the adjuvant setting only, 40% in the metastatic setting only, and 19% in both metastatic and adjuvant settings. Fifty-nine percent received study medicinal product as second or greater than second-line therapy. Seventy-seven percent of the patients had been previously exposed to anthracyclines.



Results for overall response rate and time to disease progression, and progression-free survival and survival for patients receiving > 1st-line therapy, are shown below.












































Table 2: Results for overall response rate, median time to disease progression, and progression-free survival as assessed by the investigator


   


Efficacy variable




Abraxane



(260 mg/m2)




Solvent-based paclitaxel



(175 mg/m2)




p-value




Response rate [95% CI] (%)


   


> 1st-line therapy




26.5 [18.98, 34.05] (n = 132)




13.2 [7.54, 18.93] (n = 136)




0.006a




*Median time to disease progression [95% CI] (weeks)


   


> 1st-line therapy




20.9 [15.7, 25.9] (n = 131)




16.1 [15.0, 19.3] (n = 135)




0.011b




*Median Progression Free Survival [95% CI] (weeks)


   


> 1st-line therapy




20.6 [15.6, 25.9] (n = 131)




16.1 [15.0, 18.3] (n = 135)




0.010b




*Survival [95% CI] (weeks)


   


> 1st-line therapy




56.4 [45.1, 76.9] (n = 131)




46.7 [39.0, 55.3] (n = 136)




0.020b



*This data is based on Clinical Study Report: CA012-0 Addendum dated Final (23 March-2005)



a Chi-squared test



b Log-rank test



229 patients treated with Abraxane in the randomized, controlled clinical trial were evaluated for safety. Neurotoxictiy to paclitaxel was evaluated through improvement by one grade for patients experiencing grade 3 peripheral neuropathy at any time during therapy. The natural course of peripheral neuropathy to resolution to baseline due to cumulative toxicity of Abraxane after > 6 courses of treatment was not evaluated and remains unknown.



Paediatric population



The European Medicines Agency has waived the obligation to submit the results of studies with Abraxane in all subsets of the paediatric population in the treatment of metastatic breast cancer (see section 4.2 for information on paediatric use).



5.2 Pharmacokinetic Properties



The pharmacokinetics of total paclitaxel following 30- and 180-minute infusions of Abraxane at dose levels of 80 to 375 mg/m2 were determined in clinical studies. The paclitaxel exposure (AUC) increased linearly from 2653 to 16736 ng.hr/ml following dosing from 80 to 300 mg/m2.



Following intravenous administration of Abraxane to patients with metastatic breast cancer at the recommended clinical dose of 260 mg/m2, paclitaxel plasma concentrations declined in a multiphasic manner. The mean Cmax of paclitaxel, which occurred at the end of the infusion, was 18.7 µg/ml. The mean total clearance was 15 l/hr/m2. The terminal half-life was about 27 hours. The mean volume of distribution was 632 l/m2; the large volume of distribution indicates extensive extravascular distribution and/or tissue binding of paclitaxel.



In a study in patients with advanced solid tumours, the pharmacokinetic characteristics of paclitaxel following Abraxane administered intravenously at 260 mg/m2 over 30 minutes were compared with those following 175 mg/m2 of the solvent-based paclitaxel injection administered over 3 hours. The clearance of paclitaxel with Abraxane was larger (43%) than that following a solvent-based paclitaxel injection and its volume of distribution was also higher (53%). Differences in Cmax and Cmax corrected for dose reflected differences in total dose and rate of infusion. There were no differences in terminal half-lives.



In a repeat dose study with 12 patients receiving Abraxane administered intravenously at the approved dose, intrapatient variability in systemic paclitaxel exposure (AUCinf) was 19% (range = 3.21%-27.70%). There was no evidence for accumulation of paclitaxel with multiple treatment courses.



An analysis of patient exposure (AUCinf) against bodyweight indicated a trend toward reduced AUC at 260 mg/m2 Abraxane, with decreased body weight. Patients weighing 50 kg had paclitaxel AUC approximately 25% lower than those weighing 75 kg. The clinical relevance of this finding is uncertain.



The protein binding of paclitaxel following Abraxane was evaluated by ultrafiltration. The fraction of free paclitaxel was significantly higher with Abraxane (6.2%) than with solvent-based paclitaxel (2.3%). This resulted in significantly higher exposure to unbound paclitaxel with Abraxane compared with solvent-based paclitaxel, even though the total exposure is comparable. This is possibly due to paclitaxel not being trapped in Cremophor EL micelles as with solvent-based paclitaxel. Based on the published literature, in vitro studies of binding to human serum proteins, (using paclitaxel at 6µM) the presence of ranitidine, dexamethasone, or diphenhydramine did not affect protein binding of paclitaxel.



Based on the published literature, in vitro studies with human liver microsomes and tissue slices show that paclitaxel is metabolised primarily to 6α-hydroxypaclitaxel; and to two minor metabolites, 3'-p-hydroxypaclitaxel and 6α-3'-p-dihydroxypaclitaxel. The formation of these hydroxylated metabolites is catalysed by CYP2C8, -3A4, and both -2C8 and -3A4 respectively.



The pharmacokinetic profile of Abraxane administered as a 30 minute infusion was evaluated in 15 out of 30 patients with three levels of hepatic impairment based on serum bilirubin and liver enzyme levels. Figure 1 shows the correlation between paclitaxel clearance and total blood bilirubin as measured just prior to dosing.



Figure 1 Correlation between paclitaxel clearance and total blood bilirubin







Paclitaxel clearance (ml/h/m2)



 


Total bilirubin (µmol/l)



The effect of renal dysfunction on the disposition of paclitaxel has not been formally investigated.



In patients with metastatic breast cancer, after a 30 minute infusion of Abraxane at 260 mg/m2, the mean value for cumulative urinary excretion of unchanged active substance accounted for 4% of the total administered dose with less than 1% as the metabolites 6α-hydroxypaclitaxel and 3'-p-hydroxypaclitaxel, indicating extensive non-renal clearance. Paclitaxel is principally eliminated by hepatic metabolism and biliary excretion.



Pharmacokinetics of paclitaxel in patients aged over 65 years seems comparable to that in patients less than 65 years. However, little information in patients over 75 years is available as only 3 patients over 75 years of age where included in the pharmacokinetic analysis.



5.3 Preclinical Safety Data



The carcinogenic potential of paclitaxel has not been studied. However, based on the published literature, paclitaxel is a potentially carcinogenic and genotoxic agent at clinical doses, based upon its pharmacodynamic mechanism of action. Paclitaxel has been shown to be clastogenic in vitro (chromosome aberrations in human lymphocytes) and in vivo (micronucleus test in mice). Paclitaxel has been shown to be genotoxic in vivo (micronucleus test in mice), but it did not induce mutagenicity in the Ames test or the Chinese hamster ovary/hypoxanthine-guanine phosphoribosyl transferase (CHO/HGPRT) gene mutation assay.



Paclitaxel at doses below the human therapeutic dose was associated with low fertility and foetal toxicity in rats. Animal studies with Abraxane showed non-reversible, toxic effects on the male reproductive organs at clinically relevant exposure levels.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Human albumin solution (containing sodium, sodium caprylate and N-acetyl DL tryptophanate).



6.2 Incompatibilities



This medicinal product must not be mixed with other medicinal products except those mentioned in section 6.6.



6.3 Shelf Life



Unopened vials: 3 years



Stability of reconstituted suspension in the vial:



After first reconstitution, the suspension should be filled into an infusion bag immediately. However, chemical and physical in use stability has been demonstrated for 8 hours at 2°C-8°C in the original carton, and protected from bright light. Alternative light-protection may be used in the clean room.



Stability of the reconstituted suspension in the infusion bag:



After reconstitution, the reconstituted suspension in the infusion bag should be used immediately. However chemical and physical in use stability has been demonstrated for 8 hours not above 25°C.



6.4 Special Precautions For Storage



Unopened vials:



This medicinal product does not require any special temperature storage conditions.



Keep the vial in the outer carton in order to protect from light.



Reconstituted suspension:



For storage conditions of the reconstituted medicinal product, see section 6.3.



6.5 Nature And Contents Of Container



50 ml vial (type 1 glass) with a stopper (butyl rubber), with an overseal (aluminium), containing 100 mg paclitaxel (as paclitaxel albumin).



Pack size of one vial.



6.6 Special Precautions For Disposal And Other Handling



Preparation and administration precautions:



Paclitaxel is a cytotoxic anticancer medicinal product and, as with other potentially toxic compounds, caution should be exercised in handling Abraxane. The use of gloves, goggles and protective clothing is recommended. If the suspension contacts the skin, the skin should be washed immediately and thoroughly with soap and water. If it contacts mucous membranes, the membranes should be flushed thoroughly with water. Abraxane should only be prepared and administered by personnel appropriately trained in the handling of cytotoxic agents. Pregnant staff should not handle Abraxane.



Given the possibility of extravasation, it is advisable to closely monitor the infusion site for possible infiltration during drug administration. Limiting the infusion of Abraxane to 30 minutes, as directed, reduces the likelihood of infusion-related reactions.



Reconstitution and administration of the product:



Abraxane is supplied as a sterile lyophilised powder for reconstitution before use. After reconstitution, each ml of suspension contains 5 mg of paclitaxel (as paclitaxel albumin).



Using a sterile syringe, 20 ml of sodium chloride 9 mg/ml (0.9%) solution for infusion should slowly be injected into a vial of Abraxane over a minimum of 1 minute. The solution should be directed onto the inside wall of the vial. The solution should not be injected directly onto the powder as this will result in foaming.



Once the addition is complete, the vial should be allowed to stand for a minimum of 5 minutes to ensure proper wetting of the solid. Then, the vial should gently and slowly be swirled and/or inverted for at least 2 minutes until complete resuspension of any powder occurs. The generation of foam must be avoided. If foaming or clumping occurs, the solution must stand for at least 15 minutes until foam subsides.



The reconstituted suspension should be milky and homogenous without visible precipitates. If precipitates or settling are visible, the vial should be gently inverted again to ensure complete resuspension prior to use. Some settling of the reconstituted suspension may occur. Complete resuspension should be ensured by mild agitation before use.



Discard the reconstituted suspension if precipitates are observed.



Calculate the exact total dosing volume of 5 mg/ml suspension required for the patient and inject the appropriate amount of reconstituted Abraxane into an empty, sterile, PVC or non-PVC type intravenous bag. The use of specialized DEHP-free solution containers or administration sets is not necessary to prepare or administer Abraxane infusions. In-line filters should not be used.



Any unused product or waste material should be disposed of in accordance with local requirements.



7. Marketing Authorisation Holder



Celgene Europe Limited



1 Longwalk Road



Stockley Park



Uxbridge



Middlesex



UB11 1DB



United Kingdom



8. Marketing Authorisation Number(S)



EU/1/07/428/001



9. Date Of First Authorisation/Renewal Of The Authorisation



11 January 2008



10. Date Of Revision Of The Text



07 /2011



Detailed information on this product is available on the website of the European Medicines Agency http://www.ema.europa.eu




Codeine/Dexbrompheniramine/Pseudoephedrine Liquid


Pronunciation: KOE-deen/DEX-brome-fen-IR-a-meen/SOO-doe-e-FED-rin
Generic Name: Codeine/Dexbrompheniramine/Pseudoephedrine
Brand Name: M-End Max D


Codeine/Dexbrompheniramine/Pseudoephedrine Liquid is used for:

Relieving symptoms of sinus congestion, runny nose, sneezing, itchy nose or throat, itchy or watery eyes, and cough due to colds, hay fever, or upper respiratory allergies. Codeine/Dexbrompheniramine/Pseudoephedrine Liquid may also be used for other conditions as determined by your doctor.


Codeine/Dexbrompheniramine/Pseudoephedrine Liquid is a decongestant, antihistamine, and cough suppressant combination. The decongestant works by constricting blood vessels and reducing swelling in the nasal passages. The antihistamine works by blocking the action of histamine, which helps reduce symptoms such as watery eyes and sneezing. The cough suppressant works in the brain to help decrease the cough reflex to reduce a dry cough.


Do NOT use Codeine/Dexbrompheniramine/Pseudoephedrine Liquid if:


  • you are allergic to any ingredient in Codeine/Dexbrompheniramine/Pseudoephedrine Liquid or any other codeine- or morphine-related medicine (eg, dihydrocodeine, oxycodone)

  • you have severe or uncontrolled high blood pressure, severe heart blood vessel disease, rapid heartbeat, severe heart problems, increased pressure in the brain, or slow or shallow breathing

  • you are unable to urinate or are having an asthma attack

  • you take droxidopa, sodium oxybate (GHB), or you have taken furazolidone or a monoamine oxidase inhibitor (MAOI) (eg, phenelzine) within the last 14 days

Contact your doctor or health care provider right away if any of these apply to you.



Before using Codeine/Dexbrompheniramine/Pseudoephedrine Liquid:


Some medical conditions may interact with Codeine/Dexbrompheniramine/Pseudoephedrine Liquid. Tell your doctor or pharmacist if you have any medical conditions, especially if any of the following apply to you:


  • if you are pregnant, planning to become pregnant, or are breast-feeding

  • if you are taking any prescription or nonprescription medicine, herbal preparation, or dietary supplement

  • if you have allergies to medicines, foods, or other substances

  • if you have a history of adrenal gland problems (eg, adrenal gland tumor), heart problems (eg, cor pulmonale; fast, slow, or irregular heartbeat; heart disease), high or low blood pressure, liver problems, low blood volume, diabetes, blood vessel problems, stroke, glaucoma or increased pressure in the eye, thyroid problems, or trouble sleeping

  • if you have a history of asthma, chronic obstructive pulmonary disease (COPD), or other lung or breathing problems (eg, chronic bronchitis, emphysema, sleep apnea, slow or irregular breathing), or chronic cough, or if your cough occurs with large amounts of mucus

  • if you have severe drowsiness, recent head or brain injury, brain tumor or lesions, increased pressure in the brain, infection of the brain or nervous system, or a seizure disorder (eg, epilepsy)

  • if you have a history of constipation, stomach problems (eg, ulcers), bowel problems (eg, chronic inflammation, ulceration of the bowel, or diarrhea due to antibiotic use); gallbladder problems (eg, gallstones); a blockage of your stomach, bladder, or bowels; trouble urinating; an enlarged prostate or other prostate problems; or if you have had recent stomach, bowel, or urinary surgery

  • if you have a history of alcohol abuse, drug abuse, mental or mood problems (eg, depression), or suicidal thoughts or behavior, or if you are in poor health or are very overweight

  • if you are taking medicine for high blood pressure

Some MEDICINES MAY INTERACT with Codeine/Dexbrompheniramine/Pseudoephedrine Liquid. Tell your health care provider if you are taking any other medicines, especially any of the following:


  • Digoxin or droxidopa because the risk of irregular heartbeat or heart attack may be increased

  • Furazolidone, linezolid, or MAOIs (eg, phenelzine) because severe high blood pressure and fever may occur

  • Barbiturates (eg, phenobarbital), beta-blockers (eg, propranolol), cimetidine, HIV protease inhibitors (eg, ritonavir), muscle relaxants (eg, cyclobenzaprine), opioid analgesics (eg, hydrocodone), phenothiazines (eg, chlorpromazine), sodium oxybate (GHB), tricyclic antidepressants (eg, amitriptyline), or urinary alkalinizers (eg, sodium bicarbonate) because they may increase the risk of Codeine/Dexbrompheniramine/Pseudoephedrine Liquid's side effects

  • Anticholinergics (eg, scopolamine) because a serious bowel motility problem (paralytic ileus) may occur

  • Quinidine or rifamycins (eg, rifampin) because they may decrease Codeine/Dexbrompheniramine/Pseudoephedrine Liquid's effectiveness

  • Naltrexone because it may decrease Codeine/Dexbrompheniramine/Pseudoephedrine Liquid's effectiveness. Withdrawal symptoms may also occur in patients who are physically dependent on opioids. Do not take naltrexone until you have stopped taking Codeine/Dexbrompheniramine/Pseudoephedrine Liquid for 7 to 10 days and you have had a negative naloxone challenge test

  • Bromocriptine or hydantoins (eg, phenytoin) because the risk of their side effects may be increased by Codeine/Dexbrompheniramine/Pseudoephedrine Liquid

  • Guanadrel, guanethidine, mecamylamine, methyldopa, or reserpine because their effectiveness may be decreased by Codeine/Dexbrompheniramine/Pseudoephedrine Liquid

This may not be a complete list of all interactions that may occur. Ask your health care provider if Codeine/Dexbrompheniramine/Pseudoephedrine Liquid may interact with other medicines that you take. Check with your health care provider before you start, stop, or change the dose of any medicine.


How to use Codeine/Dexbrompheniramine/Pseudoephedrine Liquid:


Use Codeine/Dexbrompheniramine/Pseudoephedrine Liquid as directed by your doctor. Check the label on the medicine for exact dosing instructions.


  • Take Codeine/Dexbrompheniramine/Pseudoephedrine Liquid by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.

  • Take Codeine/Dexbrompheniramine/Pseudoephedrine Liquid with a full glass of water (8 oz/240 mL).

  • Drink plenty of water while taking Codeine/Dexbrompheniramine/Pseudoephedrine Liquid.

  • Use a measuring device marked for medicine dosing. Ask your pharmacist for help if you are unsure of how to measure your dose.

  • If you miss a dose of Codeine/Dexbrompheniramine/Pseudoephedrine Liquid and you are taking it regularly, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Codeine/Dexbrompheniramine/Pseudoephedrine Liquid.



Important safety information:


  • Codeine/Dexbrompheniramine/Pseudoephedrine Liquid may cause drowsiness, dizziness, or blurred vision. These effects may be worse if you take it with alcohol or certain medicines. Use Codeine/Dexbrompheniramine/Pseudoephedrine Liquid with caution. Do not drive or perform other possibly unsafe tasks until you know how you react to it.

  • Codeine/Dexbrompheniramine/Pseudoephedrine Liquid may cause dizziness, light-headedness, or fainting; alcohol, hot weather, exercise, or fever may increase these effects. To prevent them, sit up or stand slowly, especially in the morning. Sit or lie down at the first sign of any of these effects.

  • Do not drink alcohol while you are taking Codeine/Dexbrompheniramine/Pseudoephedrine Liquid.

  • Check with your doctor before you use medicines that may cause drowsiness (eg, muscle relaxers, sleep aids) while you are using Codeine/Dexbrompheniramine/Pseudoephedrine Liquid; it may add to their effects. Ask your pharmacist if you have questions about which medicines may cause drowsiness.

  • Do not take diet or appetite control medicines while you take Codeine/Dexbrompheniramine/Pseudoephedrine Liquid without checking with your doctor.

  • Codeine/Dexbrompheniramine/Pseudoephedrine Liquid has a decongestant, antihistamine, and cough suppressant in it. Before you start any new medicine, check the label to see if it has a decongestant, antihistamine, or cough suppressant in it too. If it does or if you are not sure, check with your doctor or pharmacist.

  • Do not use Codeine/Dexbrompheniramine/Pseudoephedrine Liquid for a cough with a lot of mucus. Do not use it for a long-term cough (eg, caused by asthma, emphysema, smoking). However, you may use it for these conditions if your doctor tells you to.

  • Do NOT take more than the recommended dose or use for longer than prescribed without checking with your doctor.

  • If new symptoms occur, or if cough or nasal congestion persists for more than 1 week, gets worse or returns, or occurs along with a fever, rash, or persistent headache, check with your doctor. A persistent cough may be a sign of a serious condition.

  • Codeine/Dexbrompheniramine/Pseudoephedrine Liquid may cause you to become sunburned more easily. Avoid the sun, sunlamps, or tanning booths until you know how you react to Codeine/Dexbrompheniramine/Pseudoephedrine Liquid. Use a sunscreen or wear protective clothing if you must be outside for more than a short time.

  • Codeine/Dexbrompheniramine/Pseudoephedrine Liquid may interfere with skin allergy tests. If you are scheduled for a skin test, talk to your doctor. You may need to stop taking Codeine/Dexbrompheniramine/Pseudoephedrine Liquid for a few days before the tests.

  • Tell your doctor or dentist that you take Codeine/Dexbrompheniramine/Pseudoephedrine Liquid before you receive any medical or dental care, emergency care, or surgery.

  • Use Codeine/Dexbrompheniramine/Pseudoephedrine Liquid with caution in the ELDERLY; they may be more sensitive to its effects, especially confusion, dizziness, drowsiness, low blood pressure, excitability, dry mouth, and trouble urinating.

  • Caution is advised when using Codeine/Dexbrompheniramine/Pseudoephedrine Liquid in CHILDREN; they may be more sensitive to its effects, especially excitability.

  • Codeine/Dexbrompheniramine/Pseudoephedrine Liquid should not be used in CHILDREN younger than 6 years old without first checking with the child's doctor; safety and effectiveness in these children have not been confirmed. They may be at greater risk for severe and possibly fatal breathing problems.

  • PREGNANCY and BREAST-FEEDING: If you become pregnant, contact your doctor. You will need to discuss the benefits and risks of using Codeine/Dexbrompheniramine/Pseudoephedrine Liquid while you are pregnant. Codeine/Dexbrompheniramine/Pseudoephedrine Liquid is found in breast milk. Do not breast-feed while taking Codeine/Dexbrompheniramine/Pseudoephedrine Liquid.

When used for long periods of time or at high doses, Codeine/Dexbrompheniramine/Pseudoephedrine Liquid may not work as well and may require higher doses to obtain the same effect as when originally taken. This is known as TOLERANCE. Talk with your doctor if Codeine/Dexbrompheniramine/Pseudoephedrine Liquid stops working well. Do not take more than prescribed.


Some people who use Codeine/Dexbrompheniramine/Pseudoephedrine Liquid for a long time may develop a need to continue taking it. People who take high doses are also at risk. This is known as DEPENDENCE or addiction.


If you suddenly stop taking Codeine/Dexbrompheniramine/Pseudoephedrine Liquid, you may experience WITHDRAWAL symptoms including anxiety; diarrhea; fever, runny nose, or sneezing; goose bumps and abnormal skin sensations; nausea; vomiting; pain; rigid muscles; rapid heartbeat; seeing, hearing, or feeling things that are not there; shivering or tremors; sweating; and trouble sleeping.



Possible side effects of Codeine/Dexbrompheniramine/Pseudoephedrine Liquid:


All medicines may cause side effects, but many people have no, or minor, side effects. Check with your doctor if any of these most COMMON side effects persist or become bothersome:



Anxiety; constipation; dizziness; drowsiness; dry mouth, nose, or throat; excitability; headache; loss of appetite; nausea; trouble sleeping; upset stomach; vomiting; weakness.



Seek medical attention right away if any of these SEVERE side effects occur:

Severe allergic reactions (rash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); confusion; difficulty urinating or inability to urinate; fainting; fast, slow, or irregular heartbeat; fever, chills, or persistent sore throat; hallucinations; loss of coordination; mental or mood changes (eg, depression, nervousness); persistent trouble sleeping; ringing in the ears; seizures; severe or persistent dizziness, light-headedness, or headache; severe drowsiness; shallow breathing; tremor; uncontrolled muscle movements; unusual bruising or bleeding; unusual weakness or tiredness; vision changes or blurred vision.



This is not a complete list of all side effects that may occur. If you have questions about side effects, contact your health care provider. Call your doctor for medical advice about side effects. To report side effects to the appropriate agency, please read the Guide to Reporting Problems to FDA.


See also: Codeine/Dexbrompheniramine/Pseudoephedrine side effects (in more detail)


If OVERDOSE is suspected:


Contact 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center, or emergency room immediately. Symptoms may include blurred vision; cold and clammy skin; coma; confusion; hallucinations; seizures; severe dizziness, light-headedness, or headache; severe drowsiness; shallow breathing; unusually fast, slow, or irregular heartbeat; vomiting.


Proper storage of Codeine/Dexbrompheniramine/Pseudoephedrine Liquid:

Store Codeine/Dexbrompheniramine/Pseudoephedrine Liquid at room temperature, between 59 and 86 degrees F (15 and 30 degrees C). Store away from heat, moisture, and light. Do not store in the bathroom. Keep Codeine/Dexbrompheniramine/Pseudoephedrine Liquid out of the reach of children and away from pets.


General information:


  • If you have any questions about Codeine/Dexbrompheniramine/Pseudoephedrine Liquid, please talk with your doctor, pharmacist, or other health care provider.

  • Codeine/Dexbrompheniramine/Pseudoephedrine Liquid is to be used only by the patient for whom it is prescribed. Do not share it with other people.

  • If your symptoms do not improve or if they become worse, check with your doctor.

  • Check with your pharmacist about how to dispose of unused medicine.

This information is a summary only. It does not contain all information about Codeine/Dexbrompheniramine/Pseudoephedrine Liquid. If you have questions about the medicine you are taking or would like more information, check with your doctor, pharmacist, or other health care provider.



Issue Date: February 1, 2012

Database Edition 12.1.1.002

Copyright © 2012 Wolters Kluwer Health, Inc.

More Codeine/Dexbrompheniramine/Pseudoephedrine resources


  • Codeine/Dexbrompheniramine/Pseudoephedrine Side Effects (in more detail)
  • Codeine/Dexbrompheniramine/Pseudoephedrine Use in Pregnancy & Breastfeeding
  • Codeine/Dexbrompheniramine/Pseudoephedrine Drug Interactions
  • Codeine/Dexbrompheniramine/Pseudoephedrine Support Group
  • 0 Reviews for Codeine/Dexbrompheniramine/Pseudoephedrine - Add your own review/rating


Compare Codeine/Dexbrompheniramine/Pseudoephedrine with other medications


  • Cough and Nasal Congestion